Parvovirus B19 Antibodies, IgG and IgM, Serum
Use
This test is useful for diagnosing recent or past parvovirus B19 infections by detecting IgG and IgM antibodies in serum. Parvovirus B19 is known to cause fifth disease and can lead to complications such as fetal damage during pregnancy. Serologic detection is essential for identifying acute infections and assessing serostatus, which can inform clinical decision-making, especially in pregnant women and immunocompromised patients.
Special Instructions
The test is intended for patients with at least 7 days of symptoms or asymptomatic individuals with recent exposure to parvovirus B19. This assay may help determine the serostatus of patients at risk for infection with parvovirus B19. Testing should be coordinated using the Infectious Disease Serology Test Request form if not ordered electronically.
Limitations
Specimens collected prior to seroconversion may yield negative IgM or IgG results. The performance characteristics have not been established for matrices other than serum, neonates, and immunocompromised patients. Antinuclear antibodies or Epstein-Barr virus-positive specimens may produce false-positive or equivocal IgM results. This test is not to be used as a screening procedure for the general population. Testing is indicated only when clinical evidence suggests parvovirus B19-associated disease.
New York Approved
Methodology
Immunoassay (EIA)
Biomarkers
LOINC Codes
- 34950-6
- 29660-8
- 40658-7
- 58737-8
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.5 mL
Minimum Volume
0.4 mL
Container
Plastic vial
Collection Instructions
Centrifuge and aliquot serum into a plastic vial.
Causes for Rejection
Gross hemolysis, gross lipemia, gross icterus, heat-inactivated specimens
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 14 days |
| Frozen | 14 days |